Duncan Williams Asset Management LLC Takes $206,000 Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Duncan Williams Asset Management LLC has acquired a new stake of 509 shares in Thermo Fisher Scientific, valued at approximately $206,000, according to their recent Form 13F filing.
• Recent analyst reports have increased price targets for Thermo Fisher Scientific's shares, with UBS raising it to $500 and Barclays to $585, indicating strong market confidence.
• The company announced a quarterly dividend of $0.43 per share, with a yield of 0.3%, confirming a steady income return for shareholders.

Duncan Williams Asset Management LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 509 shares of the medical research company's stock, valued at approximately $206,000.

Other large investors also recently modified their holdings of the company. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Root Financial Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after purchasing an additional 24 shares in the last quarter. Rossmore Private Capital boosted its position in shares of Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock valued at $2,315,000 after buying an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in Thermo Fisher Scientific by 3.1% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock valued at $326,000 after buying an additional 24 shares during the last quarter. Finally, Family Legacy Inc. lifted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Family Legacy Inc. now owns 2,690 shares of the medical research company's stock valued at $1,339,000 after acquiring an additional 26 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. UBS Group increased their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research report on Thursday. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Finally, Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $585.37.

Thermo Fisher Scientific Stock Up 0.2%

Shares of NYSE TMO opened at $544.44 on Tuesday. The business's fifty day moving average price is $483.77 and its 200-day moving average price is $446.95. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock has a market capitalization of $205.59 billion, a PE ratio of 31.49, a P/E/G ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last three months. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.